Precipio Inc. stock gains on Q2 2026 revenue growth and path to profitability

Published on 09/19/2026 at 10:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Precipio Inc. stock is supported by Q2 2026 revenue rising about 22 percent year over year to more than USD 7 million. The company also moved toward profitability in the period as losses narrowed versus the prior year.

PRPO, US74019G1040, Illustration mit AI erstellt.

Precipio Inc. stock (ISIN US74019G1040) is drawing investor attention after the diagnostics company reported second-quarter 2026 revenue of more than USD 7 million, representing around 22 percent year-over-year growth as of the Q2 2026 report date.

Q2 2026 revenue growth and earnings shift

According to Scanx Trade on September 18, 2026, Precipio Inc. reported record second-quarter 2026 revenues exceeding USD 7 million, marking about a 22 percent increase compared with the same quarter a year earlier.

As Scanx Trade reports, the company also moved toward profitability in Q2 2026, with the article highlighting a shift from a profit in the prior-year quarter to a loss of USD 0.12 per share, underlining the volatility of earnings as Precipio continues to scale its diagnostics platform.

Operational momentum and investor view

For investors, the roughly 22 percent revenue growth in Q2 2026 stands out as a key signal that demand for Precipio's diagnostic solutions is expanding relative to the second quarter of 2025. The jump to more than USD 7 million in quarterly revenue gives the company a larger base from which to pursue operating leverage in the coming quarters.

The Q2 2026 performance also underscores how Precipio is balancing growth investments with the aim of achieving consistent profitability, as the movement in earnings per share compared with the prior year highlights both progress and remaining work on cost control and mix.

Stock level and market context

As of September 18, 2026, the most recent completed trading day, Precipio Inc. stock on Nasdaq in USD reflects the market's assessment of these Q2 2026 figures, with the price positioning the shares relative to their 52-week range and the company’s market capitalization in the diagnostics segment.